BLOG / 🇺🇸 United States / broad market · · daily

US SEC Filings Daily Market Digest — November 09, 2026

Daily USA Market Intelligence

By Gunpowder Editorial ·

23 high priority 27 medium priority 50 total filings analysed

Executive Summary

Today's 50-filing digest is dominated by Q3 2026 earnings and deal flow, revealing a market of stark haves and have-nots.

Mega-cap tech exposure remains the backbone of institutional 13F portfolios (Danske $50.1B, Danica $6.26B, Migdal $2.1B+), but the real action is in idiosyncratic corporate events: QXO's 79% revenue growth via M&A, Dole's guidance cut on cost inflation, Edesa's $140M+ Kyorin licensing deal, and a wave of SPAC/IPO registrations (Rezera, Research Alliance V, ZA Acquisition, SPACCircle). Period comparisons show margin pressure is pervasive—Dole cut FY26 EBITDA guidance to $380-390M from ~$400M, QXO's GAAP loss persists despite 85% EBITDA growth, and Scinai's gross loss widened despite 167% revenue growth. Insider activity is mixed: Gamehaus's chairman increased his stake to 31.5% via a share-based acquisition, while Vistance's CEO is departing and Datavault's CEO was removed. Capital allocation signals are strong: Corebridge is buying back $110M of stock, FTAI refinanced $1B of debt, and Prudential repurchased 2.75M shares. The most actionable themes are biotech catalysts (Cabaletta's positive Phase 1/2 data, Edesa's partnership, Rezera's IPO), M&A arbitrage (Option Care Health merger, tZERO SPAC), and distressed situations (Synlogic/Caldera reverse merger, Datavault leadership turmoil).

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Filing types in this digest: 13F · 8-K · 10-Q · S-1 · DEF 14A · Schedule 13D · Schedule 13G · 425 · DEFM14A

Tracking the trend? Catch up on the prior US SEC Filings Daily Market Digest digest from November 06, 2026.

Investment Signals (12)

  • QXO, Inc. ↓ (BULLISH)
    ▲

    Q3 2026 net sales surged 79% YoY to ~$4.90B and Adjusted EBITDA jumped 85% to ~$557M, driven by Kodiak and TopBuild acquisitions; however, GAAP net loss of ~$123M and interest expense of $163M (vs $37M) highlight integration costs and leverage. Full Q3 results on Nov 12 could be a catalyst if margin trends improve.

  • Signed a $140M+ exclusive license with KYORIN for paridiprubart in Japan, including $12M upfront and up to $134M in milestones plus double-digit royalties. Kyorin funds all Japanese development, providing non-dilutive validation and near-term cash. Phase 3 28-day mortality data was statistically significant (p<0.001).

  • New rese-cel Phase 1/2 data show 100% (6/6) dermatomyositis patients maintained TIS responses through one year, and all 5 biopsied lupus nephritis patients achieved DORIS remission. No IEC-HS across 71 patients. Registrational topline in 2H 2027 and BLA targeted 1Q 2028 provide a clear catalyst path.

  • Q3 2026 total revenues rose 11.2% YoY to $105.6B, but net earnings fell 28.2% to $22.1B on lower investment gains. Nine-month net earnings rose 21.2% to $57.9B, helped by equity method earnings swinging to +$1.4B from -$4.3B. Cash pile remains massive at $36B. [NEUTRAL/BULLISH]

  • Agreed to repurchase ~$110M of common stock from Argon Holdco at $34.09/share (Nov 6 close), expected to close Nov 10. This buyback signals management confidence and provides support at current levels.

  • Issued $1.0B of 7.125% Senior Notes due 2034 to repay its revolver and redeem $500M of 5.50% 2028 notes. The refinancing extends maturities but increases coupon cost by 162.5 bps; leverage-neutral and improves liquidity.

  • Chairman Xie Feng and affiliates now own 31.5% of Class A shares after acquiring Techforge for $19.6M in stock. Insider concentration increased by 21.1% of prior shares outstanding, aligning interests but reducing float.

  • Dole plc ↓ (BEARISH)
    ▲

    Q3 revenue rose 3.8% to $2.37B and net income jumped to $38.5M from $5.1M, but gross profit rose only 8.7% and nine-month gross profit declined 1.2%. Management cut FY26 Adjusted EBITDA guidance to $380-390M from ~$400M on higher fuel, shipping, and El Niño costs.

  • 9M 2026 revenue grew 167% to $2.805M, but gross loss widened to $2.971M as cost of revenues rose 95% to $5.776M. Net loss narrowed to $0.393M only due to a one-time $6.401M bargain purchase gain; operating loss deepened to $6.563M. Cash fell to $1.907M.

  • Filed DEFM14A for a merger expected to close in 1H 2027, after which shares will be delisted. The proxy details termination fees and appraisal rights; merger arbitrage opportunity exists but regulatory approval is a risk.

  • ▲

    Repurchased 2.75M shares over five days (Nov 2-6) at a VWAP declining to 9.2335 on Nov 6 from 9.5891 on Nov 4, indicating accelerated buybacks at lower prices. This supports EPS and signals undervaluation.

  • Rezera Inc. ↓ (SPECULATIVE BULLISH)
    ▲

    Filed S-1/A for a $181M Nasdaq IPO at $12/share midpoint; GSK has a right-of-first-negotiation and may purchase up to 10% of the offering. Pre-revenue with widening losses ($42.2M in FY2025), but proceeds fund Phase 3 through 2028. High-risk biotech IPO with big pharma validation.

Risk Flags (10)

  • Dole plc↓ [HIGH RISK]
    ▼

    Cut FY26 Adjusted EBITDA guidance to $380-390M from ~$400M, citing elevated fuel, shipping, and El Niño costs. Nine-month Adjusted EBITDA fell 12.1% to $301.1M, and Fresh Fruit segment Adjusted EBITDA dropped sharply to $131.6M from $163.2M.

  • Gross loss widened to $2.971M from $1.909M as cost of revenues ($5.776M) exceeded revenues ($2.805M). Operating loss deepened to $6.563M, and cash fell to $1.907M from $3.150M. The net loss improvement was entirely due to a one-time $6.401M bargain purchase gain.

  • Datavault AI Inc.↓ [HIGH RISK]
    ▼

    CEO Nathaniel Bradley was removed on Nov 1, 2026, and the company flagged risks including a restatement of previously issued financial statements, Nasdaq minimum bid price compliance, potential reverse stock split, and possible litigation tied to executive removals.

  • Synlogic is a non-operating shell delisted from Nasdaq with a material weakness in internal controls. Caldera is early-stage with no product revenue and dependence on a single candidate. Completion is conditioned on NYSE American listing approval and a concurrent financing, with failure risking Synlogic's dissolution.

  • QXO, Inc.↓ [MODERATE RISK]
    ▼

    Despite 79% revenue growth, GAAP net loss of ~$123M and interest expense of $163M (up from $37M) reflect heavy debt from acquisitions. Integration risk remains high, and full Q3 results on Nov 12 could reveal further costs.

  • Shareholders' deficit of $7.65M as of Sep 30, 2026, versus positive equity of $7,093 at year-end 2025, due to $16.17M accretion to redemption value. Operating losses widened with G&A of $377K for nine months.

  • ▼

    Entered a convertible note purchase agreement with Esousa Group Holdings, but no principal, interest rate, or conversion price disclosed. Capitalization shows 236M common shares outstanding against 475M reserved for convertible securities, implying massive potential dilution.

  • Laredo Oil, Inc.↓ [MODERATE RISK]
    ▼

    Increased authorized common stock from 120M to 350M shares (2.9x) via majority written consent, with 48.6% of shares not participating. This signals potential dilution and lack of broad shareholder support.

  • Tivic Health Systems (Valion Bio) [MODERATE RISK]
    ▼

    Closed a $700K tranche of Series B preferred with 3i, LP, triggering anti-dilution price adjustments across existing Series B, Series C, and note securities. The raise is small relative to $13.6M drawn on a $75M Series C program and a $16.25M senior secured convertible note.

  • Three of four director nominees received ~4.4% withheld votes (120,999 shares each), indicating shareholder dissent. While not material financially, it signals governance concerns.

Opportunities (10)

  • Edesa Biotech, Inc.↓ (OPPORTUNITY)
    ◆

    The $140M+ Kyorin deal provides non-dilutive cash and validates paridiprubart. Upfront $12M extends runway, and milestones could fund Phase 3. Kyorin also has a right of first negotiation for AKI, expanding potential.

  • Cabaletta Bio, Inc.↓ (OPPORTUNITY)
    ◆

    Strong Phase 1/2 data in dermatomyositis and lupus nephritis with no IEC-HS. Registrational topline in 2H 2027 and BLA in 1Q 2028 are clear catalysts. The stock may be undervalued given the unmet need and potential best-in-class profile.

  • Rezera Inc. IPO↓ (OPPORTUNITY)
    ◆

    GSK's right-of-first-negotiation and potential 10% stake purchase ($25M) provide big pharma validation. Proceeds fund ruvonoflast Phase 3 through 2028 topline. IPO expected soon; watch for pricing and GSK's actual participation.

  • The merger is expected to close in 1H 2027, and the spread may widen on regulatory news. The DEFM14A details termination fees and appraisal rights. Monitor for stockholder vote date and regulatory approvals.

  • tZERO Group / FG Imperii Acquisition Corp. SPAC (OPPORTUNITY)
    ◆

    tZERO is valued at $350M pre-money, with up to $231M in trust. It received CFTC registration as a derivatives clearing organization in October 2026 and has a pending DCM application. Closing expected early 2027 under ticker TZRO.

  • The $110M repurchase at $34.09/share from Argon Holdco removes a large block and signals confidence. The stock may see support and potential further buybacks.

  • ◆

    Accelerated repurchases at declining prices (VWAP 9.2335 on Nov 6) suggest management sees value. The program could continue, supporting the stock.

  • With $36B in cash and $20.5B payable for Treasury bills, Berkshire is building dry powder. Any major acquisition or investment announcement could be a catalyst.

  • If QXO can integrate Kodiak and TopBuild and improve margins, the stock could re-rate. Full Q3 results on Nov 12 and any guidance for Q4 will be key.

  • Cohu Inc. Equity Plan↓ (OPPORTUNITY)
    ◆

    Stock rose 67.8% from March to October 2026, and the new 2026 Equity Incentive Plan has 3.44M shares available for grant (vs 1.31M previously), which could attract talent and align incentives.

Sector Themes (6)

  • M&A and SPAC Resurgence (THEME)
    ◆

    Multiple filings (QXO, Option Care Health, tZERO/FG Imperii, TruGolf/Polymath, Sonic/Caldera, Gamehaus/Techforge) show a vibrant M&A environment. SPAC IPOs (Research Alliance V, ZA Acquisition, SPACCircle) are also active, indicating risk appetite.

  • Biotech Catalysts and Partnerships (THEME)
    ◆

    Edesa's $140M+ deal, Cabaletta's positive data, and Rezera's IPO with GSK validation highlight a strong biotech catalyst cycle. Investors should watch for milestone payments and regulatory decisions.

  • Margin Pressure in Consumer/Industrial (THEME)
    ◆

    Dole cut guidance on cost inflation, QXO's GAAP loss persists, and Scinai's gross loss widened. Input cost pressures (fuel, shipping, materials) are squeezing margins despite revenue growth.

  • Institutional Portfolios Concentrated in Mega-Cap Tech (THEME)
    ◆

    13F filings from Danske, Danica, Migdal, and others show heavy allocations to NVIDIA, Apple, Microsoft, Amazon, and Alphabet. This concentration poses risk if tech falters but also supports these names.

  • Capital Returns via Buybacks and Dividends (THEME)
    ◆

    Corebridge ($110M buyback), Prudential (2.75M shares repurchased), and FTAI's refinancing to fund buybacks indicate a shareholder-friendly environment. Companies are returning cash amid uncertain macro.

  • Distressed and Restructuring Situations (THEME)
    ◆

    Datavault's CEO removal and restatement risk, Synlogic's shell status, and Hyperscale's massive dilution potential are examples of distressed companies that may offer special situation opportunities.

Watch List (8)

  • Full Q3 2026 results on November 12, 2026. Watch for integration progress, margin trends, and any updated guidance. [Date: 2026-11-12]

  • Q3 2026 preliminary earnings on November 12, 2026, with conference call at 5:00 PM Seoul Time. Watch for impact of fuel costs and tariff adjustments. [Date: 2026-11-12]

  • Share repurchase expected to close on November 10, 2026. Monitor for completion and potential further buybacks. [Date: 2026-11-10]

  • Unit separation effective November 10, 2026. Watch for trading dynamics and potential business combination announcement. [Date: 2026-11-10]

  • S-1/A filed; watch for pricing and GSK's participation. IPO could price in coming weeks. [Date: TBD]

  • Special meeting date to be announced; watch for proxy filing and regulatory approvals. [Date: TBD]

  • Q3 2026 results date to be announced; watch for restatement details and potential Nasdaq compliance issues. [Date: TBD]

  • Registrational topline in 2H 2027; near-term watch for additional data presentations and regulatory interactions. [Date: 2H 2027]

Filing Analyses (50)
Danica Pension, Livsforsikringsaktieselskab 13F-HR neutral materiality 3/10

09-11-2026

Danica Pension, Livsforsikringsaktieselskab filed its Q3 2026 13F-HR disclosing a US-listed equity portfolio of 210 positions valued at approximately $6.26 billion as of September 30, 2026. The book is heavily concentrated in mega-cap technology, with NVIDIA ($510.3M), Apple ($411.5M), Microsoft ($380.5M), Alphabet Class C ($282.2M) and Amazon ($266.8M) as the largest holdings. The filing is a holdings snapshot only and contains no period-over-period comparison data, so no growth or decline metrics can be calculated.

  • · All 210 positions are held in sole voting authority with zero shared or discretionary voting power reported.
  • · Portfolio includes non-US issuers via ADRs and foreign ordinaries, e.g., Taiwan Semiconductor ADS ($56.6M), SK Hynix ADS ($15.8M), Credo Technology ($54.5M) and Nebius Group ($1.1M).
  • · Notable small/new-economy positions include SpaceX Class A ($3.0M), CoreWeave ($0.5M), Astera Labs ($0.8M), Rocket Lab ($0.3M) and Strategy Inc Class A ($0.5M).
  • · Filing signed by Jesper Lorenzen, Head of Finance Investment Administration, dated October 20, 2026, in Copenhagen.
  • · No options, puts/calls or shared-discretion positions disclosed; the entire book is long common/ordinary equity.
PRUDENTIAL PLC 6-K neutral materiality 4/10

09-11-2026

Prudential plc disclosed daily share repurchases executed on the London Stock Exchange (XLON) over five trading days from 2-6 November 2026, buying a total of 2,751,671 shares. Daily volumes rose sharply through the week, from 423,602 shares on 2 November to 840,983 on 6 November (+98.5%), while the volume-weighted average price drifted lower to 9.2335 on 6 November from 9.5891 on 4 November, indicating purchases at declining prices late in the week.

  • · All purchases were executed on the London Stock Exchange (XLON)
  • · Price ranges per day: 2 Nov 9.1520-9.4260; 3 Nov 9.2680-9.4980; 4 Nov 9.3820-9.7220; 5 Nov 9.2580-9.7500; 6 Nov 9.1680-9.3020
  • · Highest intraday price of the week was 9.7500 on 5 November 2026; lowest was 9.1520 on 2 November 2026
  • · 5 November volume of 655,868 shares was up 59.6% from 4 November's 410,855 shares
HAWAIIAN ELECTRIC INDUSTRIES INC 8-K neutral materiality 2/10

09-11-2026

Hawaiian Electric Industries filed an 8-K under Regulation FD disclosing an investor presentation (Exhibit 99, 'November 2026 EEI Investor Meetings') to be used with investors and analysts beginning November 9, 2026. The filing is a routine disclosure of presentation materials posted to the company website and contains no financial results, guidance figures, or period-over-period metrics in the filing text itself. Signed by Paul K. Ito, Senior Vice President and Chief Financial Officer of both HEI and Hawaiian Electric.

  • · Filing made under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits)
  • · Exhibit 99 is the investor presentation, posted on the company website at www.hei.com
  • · Presentation intended for use with investors, analysts and others beginning on or after November 9, 2026
  • · Information is furnished but not deemed 'filed' under Section 18 of the Exchange Act
  • · HEI common stock trades on the New York Stock Exchange under ticker HE
  • · HEI IRS Employer Identification No. 99-0208097; Hawaiian Electric EIN 99-0040500
  • · HEI principal offices: 1001 Bishop Street, Suite 2900, Honolulu, Hawaii 96813; Hawaiian Electric: 1099 Alakea Street, Suite 2200, Honolulu, Hawaii 96813
  • · Neither HEI nor Hawaiian Electric is an emerging growth company
Artificial Intelligence Technology Solutions Inc. 8-K neutral materiality 2/10

09-11-2026

Artificial Intelligence Technology Solutions Inc. (AITX) filed an 8-K on November 9, 2026, announcing that its RAD subsidiary will issue a press release titled "AITX's RAD Introduces RAIA, the Security Tower You Can Set Up Yourself." The filing is a product-launch announcement furnished under Item 8.01 and contains no financial results, revenue figures, or period-over-period metrics. The disclosure is explicitly stated not to be deemed "filed" for Section 18 purposes and carries no admission as to materiality.

  • · Filing is an 8-K under Items 8.01 (Other Events) and 9.01 (Exhibits)
  • · Press release attached as Exhibit 99.1, dated November 9, 2026
  • · Cover Page Interactive Data File embedded as Exhibit 104 (Inline XBRL)
  • · Company incorporated in Nevada; IRS Employer Identification No. 27-2343603; Commission File Number 000-55079
  • · Principal executive offices located at 10800 Galaxie Avenue, Ferndale, MI 48220
  • · No securities registered under Section 12(b); trading symbol listed as N/A
  • · Company is not an emerging growth company
  • · Signed by Steven Reinharz, Chief Executive Officer
Migdal Insurance & Financial Holdings Ltd. 13F-HR neutral materiality 4/10

09-11-2026

Migdal Insurance & Financial Holdings Ltd. filed its Q3 2026 13F-HR disclosing a large US-listed equity portfolio as of September 30, 2026, held through its subsidiaries (Migdal Insurance, Migdal Makefet, Migdal Investment Portfolio Management, and Migdal Mutual Funds). Top positions include Alphabet Class C (2,038,779 shares, $694.7M), Amazon (1,957,773 shares, $487.8M), Apple (1,464,700 shares, $487.8M), and Broadcom (384,644 shares, $135.1M). The portfolio is heavily concentrated in mega-cap technology and semiconductor names, with notable ETF exposure (iShares MSCI South Korea $285.3M, Invesco KBW Bank $270.0M, Global X Cybersecurity $149.0M), while several small positions are minimal (e.g., Deckers $1,719, Carnival $2,675).

  • · Filing is a 13F-HR for period ending September 30, 2026, filed November 9, 2026
  • · Securities held through four wholly-owned subsidiaries: Migdal Insurance, Migdal Makefet, Migdal Investment Portfolio Management, and Migdal Mutual Funds
  • · Dual-listed securities on US and Tel Aviv exchanges included only if purchased in the US, per SEC Division of Investment Management informal guidance
  • · Portfolio shows heavy concentration in mega-cap tech (Alphabet, Amazon, Apple, Broadcom) alongside significant ETF exposure
  • · Several positions are de minimis, e.g., Deckers Outdoor $1,719 (22 shares), Carnival $2,675 (109 shares), Gartner $1,865 (10 shares)
  • · CFO Itai Yanai signed the filing; contact 972-76-8868490
Dole plc 10-Q mixed materiality 7/10

09-11-2026

Dole plc reported Q3 2026 net revenue of $2,366.2M, up 3.8% YoY from $2,278.9M, and net income attributable to Dole plc of $38.5M versus $5.1M a year ago, boosted by a $48.6M gain on disposal of businesses. However, gross profit rose only 8.7% to $168.7M while nine-month gross profit declined 1.2% to $549.0M, and the Tropical Fruit segment fell 9.1% YoY to $719.0M in Q3, offsetting strong Diversified Produce growth of 11.4%.

  • · Nine-month 2026 net income attributable to Dole plc was $95.8M vs $53.9M in 2025, but comprehensive income attributable to Dole plc fell to $78.0M from $111.8M due to a $25.5M foreign currency translation loss vs a $90.8M gain prior year.
  • · Selling, marketing, general and administrative expenses rose 9.1% YoY to $399.7M for nine months, outpacing revenue growth.
  • · Nine-month 2026 diluted EPS was $1.00 vs $0.56; Q3 2026 diluted EPS $0.41 vs $0.05.
  • · Total debt reduced: long-term debt, net fell to $716.8M from $799.8M at year-end 2025; interest expense declined to $42.3M from $51.3M for nine months.
  • · Share repurchases totaled $24.6M in nine months 2026 (no buybacks in prior year period); shares outstanding fell to 93,696 thousand from 95,163 thousand.
  • · Nine-month 2026 capital expenditures were $64.4M, down from $93.1M a year earlier.
  • · Equity method earnings declined to $15.3M from $23.4M for nine months.
  • · No discontinued operations losses in 2026 vs $45.2M loss in nine months 2025.
  • · Total assets grew to $4,531.8M from $4,396.1M at December 31, 2025.
ConnectM Technology Solutions, Inc. S-1/A neutral materiality 6/10

09-11-2026

ConnectM Technology Solutions filed an S-1/A registration statement (dated November 9, 2026) containing XBRL financial data spanning FY2024 through Q2 2026, including segment results for Owned Service Network, Managed Solutions, Logistics, and Keen Labs. The filing discloses an active convertible note and warrant financing program, multiple sale-of-future-receipts agreements (including with Libertas and Air Temp Services), and related-party transactions involving the CEO and Sponsor. No clean period-over-period headline figures are extractable from the raw XBRL tags, so no reliable YoY percentage changes can be computed from this content alone.

  • · Segment reporting covers Owned Service Network, Managed Solutions, Logistics, Keen Labs, and All Other segments
  • · Convertible promissory notes and convertible debt transactions recorded against common stock and additional paid-in capital during 2025
  • · Sale of future receipts agreements executed November 7, 2025, November 13, 2025, and November 17, 2025 (the latter with Umesh Goradia/Libertas)
  • · Subsequent events include unsecured convertible promissory notes issued to investors in January, March, and April 2026
  • · Business Loan and Security Agreement dated October 27, 2025
  • · Real estate promissory note and purchase order financing arrangements disclosed as of June 30, 2026
  • · Paycheck Protection Program loans outstanding in 2024 and 2025
  • · Acquisition-related intangibles (trade names, customer relationships) tied to Air Temp Service Co Inc. and Solar Energy Systems of Brevard Inc.
  • · Noncontrolling interest activity involving Cambridge Energy Resources Ltd and Global Impex LLC
  • · Restricted stock grants to non-employee directors dated May 27, 2025, June 18, 2025, and June 23, 2025
Rezera Inc. S-1/A mixed materiality 8/10

09-11-2026

Rezera Inc. filed an amended S-1 for a Nasdaq IPO (ticker RZRA) of 16,666,667 shares at an assumed $12.00 midpoint, targeting ~$181.0M net proceeds ($208.9M if the 2,500,000-share underwriter option is fully exercised). GSK has signed a right-of-first-negotiation and clinical advisory board agreement and indicated interest in purchasing up to 2,083,333 shares (~$25.0M, ~10% of post-IPO shares), though indications are non-binding. The company is pre-revenue and loss-making: net loss widened to $25.5M in 1H 2026 from $13.7M in 1H 2025, and to $42.2M in FY2025 from $25.2M in FY2024, driven by rising R&D spend; proceeds are expected to fund ruvonoflast Phase 3 through 2028 topline data but not a trabzanoflast Phase 2 trial.

  • · Net loss per share (basic/diluted) was $(307.20) in 1H 2026 vs $(198.36) in 1H 2025, and $(583.56) in FY2025 vs $(372.92) in FY2024
  • · Pro forma net loss per share was $(7.69) in 1H 2026 vs $(13.94) in 1H 2025
  • · Pro forma weighted-average shares outstanding were 3,687,661 (1H 2026) and 3,081,553 (1H 2025)
  • · A one-for-35.722 reverse stock split was effected on November 4, 2026
  • · At the assumed offering size, net proceeds plus existing cash are NOT expected to be sufficient to fund the trabzanoflast Phase 2 proof-of-concept trial through topline data
  • · Blue Owl will exchange shares for non-voting common stock so it beneficially owns no more than 4.50% post-Exchange
  • · GSK's purchase indication is non-binding; it may buy more, fewer, or no shares
  • · Weighted-average exercise price of 2021 Plan options was $7.51; post-June 30, 2026 grants had a weighted-average exercise price of $35.37
  • · 112,307 warrants outstanding at a weighted-average exercise price of $0.47; 45,886 compensatory warrants at $35.73
  • · Foreign currency transaction loss of $1.5M in 1H 2026 vs a $2.0M gain in 1H 2025
  • · Interest income fell to $0.7M in FY2025 from $0.5M in FY2024 (and $79K in 1H 2026 vs $405K in 1H 2025)
Li Auto Inc. 6-K neutral materiality 1/10

09-11-2026

Li Auto Inc. filed a routine Form 6-K on November 9, 2026, attaching its monthly return on movements in securities for the month of November 2026, as required for Hong Kong-listed equity issuers and Hong Kong Depositary Receipts under Chapter 19B. The filing contains no financial results, operational metrics, or period-over-period performance data, and was signed by Director and CFO Tie Li. It is an administrative disclosure with no material impact on the company's financial position or outlook.

  • · Filing is a Form 6-K for the month of November 2026 under Commission File Number 001-39407
  • · Registrant files annual reports under Form 20-F
  • · Principal executive offices located at 11 Wenliang Street, Shunyi District, Beijing 101399, People's Republic of China
  • · Exhibit 99.1 is the Monthly Return for Equity Issuer and Hong Kong Depositary Receipts under Chapter 19B of the Exchange Listing Rules on Movements in Securities
  • · No financial or operational figures were disclosed in the filing
COHU INC DEF 14A neutral materiality 5/10

09-11-2026

Cohu Inc filed a DEF 14A proxy statement seeking stockholder ratification of the 2026 Equity Incentive Plan (adopted March 20, 2026, approved May 15, 2026) and a Section 204 ratification to cure an identified record-date defect; failure to ratify leaves uncertainty from the defect unresolved. The stock rose 67.8% from $28.58 (March 16, 2026) to $47.96 (October 23, 2026), while shares outstanding increased modestly from 46,903,489 to 47,346,050 (+0.9%). PSU grants fell to 396,708 in FY2025 from 202,521 in FY2024 and 270,073 in FY2023, and outstanding awards declined from 2,105,011 to 1,943,023 shares, though 3,441,157 shares remain available for grant under the 2026 Plan versus 1,314,460 previously.

  • · PSUs may be earned up to 200% of target based on performance goals
  • · 2026 Plan estimated to cover equity awards for approximately three years
  • · 2026 Plan prohibits repricing of options/SARs without stockholder approval and contains no evergreen provision, no tax gross-ups, and no liberal change-in-control definition
  • · Awards carry a minimum one-year vesting period with limited exceptions
  • · Compensation Committee considered dilution, hiring needs, stock price, and ISS guidance in sizing the 2026 Plan
Scinai Immunotherapeutics Ltd. 6-K mixed materiality 6/10

09-11-2026

Scinai Immunotherapeutics reported nine-month 2026 revenue of $2.805M, up 167% from $1.049M in 9M 2025, and sharply narrowed its net loss to $0.393M from $6.244M, aided by a one-time $6.401M gain from bargain purchase. However, gross loss widened to $2.971M from $1.909M as cost of revenues rose 95% to $5.776M, operating loss deepened to $6.563M from $5.637M, and cash fell to $1.907M at September 30, 2026 from $3.150M a year earlier.

  • · Operating loss widened to $6.563M from $5.637M despite revenue growth, as cost of revenues ($5.776M) exceeded revenues ($2.805M).
  • · Net loss improvement was driven entirely by a one-time $6.401M non-cash gain from bargain purchase; excluding it, the loss would have been roughly $6.8M.
  • · Cash received in business combination was $2.751M in 9M 2026.
  • · October 2026 financings raised ~$5.3M net, lifting bank balances to ~$8.1M as of October 27, 2026, supporting runway to late 2027.
  • · Ordinary shares outstanding rose to 54,129,107,584 from 13,872,899,584, including 20,918,960,000 pre-funded warrants and 19,058,148,000 ordinary shares issued.
  • · Authorized ordinary shares increased to 1,600,000,000,000 from 100,000,000,000.
  • · Accumulated deficit grew to $126.239M from $125.846M; accumulated other comprehensive loss widened to $2.290M from $1.740M.
  • · Non-current operating lease liabilities rose to $2.735M from $1.644M.
  • · Committed Customer Orders are an operating measure, not recognized revenue or backlog, and include authorized work scheduled for 2027.
  • · Depreciation rose to $1.560M from $1.061M.
Claritev Corp 8-K neutral materiality 4/10

09-11-2026

Claritev Corporation filed an 8-K on November 9, 2026, furnishing a press release (Exhibit 99.1) announcing financial results for the third quarter ended September 30, 2026. The filing itself contains no actual financial figures, only the cover-page disclosure and exhibit reference, so no revenue, earnings, or period-over-period comparisons can be assessed from this document alone.

  • · Q3 2026 period ended September 30, 2026; results announced via press release dated November 9, 2026
  • · Press release included as Exhibit 99.1; cover page XBRL tagged as Exhibit 104
  • · Information furnished under Item 2.02 is not deemed 'filed' under Section 18 of the Exchange Act
  • · Company incorporated in Delaware; IRS Employer Identification No. 84-3536151; Commission File Number 001-39228
  • · Principal executive offices: 7900 Tysons One Place, Suite 400, McLean, Virginia 22102
  • · Class A Common Stock trades on NYSE under ticker CTEV
  • · Company is not an emerging growth company
Edesa Biotech, Inc. 8-K positive materiality 8/10

09-11-2026

Edesa Biotech entered an exclusive collaboration and license agreement with KYORIN Pharmaceutical for development and commercialization of paridiprubart (anti-TLR4 monoclonal antibody) in Japan for ARDS, valued at more than $140 million including a $12 million upfront payment and up to approximately $134 million in development, regulatory and sales-based milestones, plus tiered double-digit royalties on net sales. Kyorin will fund all Japanese development, regulatory and commercialization activities, while Edesa retains all rights outside Japan and will manufacture and supply product. The deal provides non-dilutive validation and near-term cash, however the bulk of the value is contingent on milestone achievement and regulatory approval, and a portion of milestones is denominated in Japanese yen, exposing Edesa to FX risk.

  • · Kyorin granted a right of first negotiation for acute kidney injury (AKI) and a non-exclusive right to negotiate for other potential indications
  • · Paridiprubart treatment benefit sustained at 60 days (p=0.003) with safety profile comparable to placebo
  • · Phase 3 28-day mortality result was statistically significant (p<0.001)
  • · KYORIN founded in 1923, headquartered in Tokyo, listed on TSE (4569)
  • · Edesa's pipeline spans Medical Dermatology (EB06 for vitiligo, EB01 for chronic Allergic Contact Dermatitis) and Respiratory (paridiprubart)
  • · A portion of milestone payments is denominated in Japanese yen, creating FX exposure
  • · Edesa retains all rights to paridiprubart outside of Japan
DANSKE BANK A/S 13F-HR neutral materiality 4/10

09-11-2026

Danske Bank A/S filed its 13F-HR for the period ending September 30, 2026, disclosing a U.S. equity portfolio with total holdings valued at approximately $50.1 billion across 2,074 positions. The portfolio is heavily concentrated in mega-cap technology names, led by Amazon ($1.61B), Alphabet Class A ($1.50B), Apple ($3.18B), and Broadcom, alongside large index and sector ETF positions. The filing also discloses a modest options overlay including call positions on Apple ($16.7M) and iShares MSCI Brazil ETF ($49.9M) and put positions on Invesco QQQ ($8.9M) and Frontline PLC ($985K).

  • · Filing is a 13F-HR for reporting period September 30, 2026, filed November 9, 2026
  • · Filer is a non-U.S. entity incorporated in Denmark (Copenhagen), SEC file number 028-25849
  • · Portfolio includes both common stock and options (calls and puts) positions
  • · Notable put positions include Invesco QQQ ($8.9M), Frontline PLC ($985K), Novo-Nordisk ADR ($379K), and Strategy Inc ($101K)
  • · Notable call positions include iShares MSCI Brazil ETF ($49.9M), Apple ($16.7M), Fair Isaac ($5.9M), Frontline ($4.9M), and Teucrium Wheat ($3.7M)
  • · Large ETF/index exposure via iShares MSCI Brazil ETF and Invesco QQQ Trust
  • · Portfolio spans 2,074 reported positions indicating broad diversification across U.S. equities
  • · Signed by Per Poulsen, Head of Securities Risk & Reporting, dated November 6, 2026
Cabaletta Bio, Inc. 8-K positive materiality 7/10

09-11-2026

Cabaletta Bio disclosed new rese-cel (resecabtagene autoleucel, formerly CABA-201) Phase 1/2 clinical data at ACR Convergence 2026, highlighting immunomodulator-free durability across autoimmune diseases. All 6 dermatomyositis patients (100%) maintained moderate-to-major TIS responses through one year and all 5 biopsied lupus nephritis patients achieved DORIS remission with histologic response/remission, while systemic sclerosis showed 71% (5/7) achieving rCRISS-50 at one year. However, the data remain early-stage with small patient counts, and the registrational DM/ASyS topline is not expected until 2H 2027 with a BLA submission targeted for 1Q 2028, leaving a long path to commercialization.

  • · Data cut-off date for Phase 1/2 follow-up was September 4, 2026
  • · No immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) was reported across 71 patients
  • · Topline results from registrational adult DM/ASyS cohort anticipated in second half of 2027
  • · BLA submission for rese-cel in myositis (adult DM and available juvenile DM data) targeted for first quarter of 2028
  • · Cabaletta is enrolling a registrational systemic sclerosis cohort focused on interstitial lung disease
  • · Systemic sclerosis has one of the highest mortality rates among rheumatological conditions
  • · rese-cel construct features a fully-human CD19 binder, weight-based dosing, and a nine-day manufacturing process
  • · Data presented in one oral presentation (Abstract 0902) and two posters (Abstracts 1222 and 1673)
  • · Potential eligibility for a Priority Review Voucher based on a potential pediatric juvenile DM indication
Tuya Inc. 6-K neutral materiality 3/10

09-11-2026

Tuya Inc. filed a Form 6-K on November 9, 2026, disclosing an announcement of the date of a board meeting (Exhibit 99.1) alongside a press release (Exhibit 99.2), signed by CFO Yi (Alex) Yang. The filing itself contains no financial figures, revenue data, or period-over-period comparisons, so no quantitative performance assessment is possible from this document.

  • · Filing is a Form 6-K under the Securities Exchange Act of 1934
  • · Exhibit 99.1 is an announcement of the date of a board meeting
  • · Exhibit 99.2 is a press release
  • · Filing signed by CFO Yi (Alex) Yang on November 9, 2026
  • · No financial results, revenue, or guidance figures disclosed in the filing text
CommScope Holding Company, Inc. 8-K neutral materiality 6/10

09-11-2026

Vistance Networks (NASDAQ: VISN) announced CEO Chuck Treadway will step down as President, CEO and board member effective February 1, 2027, with the Board launching a CEO search aided by a leading executive search firm. Treadway, CEO since October 2020, oversaw divestitures, full repayment of outstanding debt and redemption of all preferred equity; including a $1.50 per share special cash distribution payable November 6, 2026, the company will have returned $16.50 per share to shareholders via special distributions in 2026. The company now operates as a focused network solutions business through Aurora Networks and separately reported Q3 2026 results the same day.

  • · Treadway has served as President and CEO since October 2020
  • · Departure effective February 1, 2027
  • · Board retained a leading executive search firm
  • · Company repaid all outstanding debt and redeemed all outstanding preferred equity
  • · Q3 2026 results released separately; conference call scheduled 8:30 am ET
  • · Ticker NASDAQ: VISN; headquarters Richardson, TX
Gamehaus Holdings Inc. SC 13D neutral materiality 7/10

09-11-2026

Xie Feng, chairman of Gamehaus Holdings Inc. (GMHS), and affiliated entities (Cyberjoy, Playfund Trust, Funomic, Funtery) filed a Schedule 13D reporting beneficial ownership of 26,598,113 Class A ordinary shares, or 31.5% of the class, following a share-based acquisition. The stake was built via a November 2, 2026 Share Purchase Agreement in which Gamehaus acquired Techforge Co., Ltd (operator of an AI-native micro-serial platform via Anamana Pte. Ltd.) for US$19,600,000, settled entirely through 24,500,000 newly issued Class A shares, of which 11,000,000 went to Cyberjoy. The newly issued shares to the Reporting Persons equaled 21.1% of Class A shares outstanding prior to the transaction, materially increasing insider concentration, while no open-market purchases occurred in the past 60 days.

  • · Share Purchase Agreement and Subscription Agreement both dated November 2, 2026
  • · Share issuance price determined via arm's-length negotiation referencing Nasdaq trading price performance
  • · No transactions in Class A shares by Reporting Persons in the past 60 days
  • · Playfund Trust is a Singapore trust with Vistra Trust (Singapore) Pte. Limited as trustee and Cyberjoy as beneficiary
  • · Xie Feng is a PRC citizen; Cyberjoy, Funomic and Funtery are BVI companies
  • · No criminal convictions or securities-law injunctions involving Reporting Persons in the last five years
  • · Reporting Persons disclaim plans for further Item 4(a)-(j) actions beyond the described transaction
KOREA ELECTRIC POWER CORP 6-K neutral materiality 3/10

09-11-2026

Korea Electric Power Corporation (KEPCO) filed a Form 6-K on November 9, 2026, announcing it plans to release preliminary unaudited consolidated earnings results for the third quarter of 2026 on November 12, 2026, followed by a conference call from 5:00 PM to 6:00 PM Seoul Time. The call will be conducted in Korean with English interpretation provided. The filing contains no actual financial figures, so no period-over-period performance can be assessed at this time.

  • · Earnings release scheduled for November 12, 2026
  • · Conference call scheduled 5:00 PM to 6:00 PM Seoul Time on November 12, 2026
  • · Conference call to be held in Korean with English interpretation
  • · Results are preliminary and unaudited, consolidated, for Q3 2026
  • · IR contact: [email protected] or +82-61-345-4211
  • · Commission File Number 001-13372; registrant files annual reports under Form 20-F
  • · Principal executive offices: 55 Jeollyeok-ro, Naju-si, Jeollanam-Gwangju, 58322, Korea
BillionToOne, Inc. SC 13D/A neutral materiality 4/10

09-11-2026

Hummingbird Ventures Management NV and affiliated Belgian funds/partners filed Amendment No. 1 to their Schedule 13D, disclosing beneficial ownership of approximately 18.49% (8,003,039 shares) of BillionToOne's Class A common stock, while partner Firat Ileri may be deemed to own 18.57% (8,034,797 shares) including RSUs. The amendment reflects only in-kind share distributions from Libertus Capital I (HV) and Fifty Years Deep, LP to Hummingbird entities, with no open-market purchases or sales in the prior 60 days. Ownership percentages are based on 43,272,198 shares outstanding as of November 2, 2026.

  • · No Reporting Person effected any transaction in Class A common stock in the 60 days preceding the filing, aside from the in-kind distributions described.
  • · Firat Ileri serves as a director of BillionToOne, Inc.
  • · Hummingbird Ventures Management NV is the managing member of all six Hummingbird Funds.
  • · Ownership percentages calculated against 43,272,198 shares outstanding as of November 2, 2026, per the Issuer's Form 10-Q filed November 4, 2026.
  • · Filing signed November 6, 2026; filed with SEC November 9, 2026.
Sohu.com Ltd 6-K neutral materiality 4/10

09-11-2026

Sohu.com Limited filed a Form 6-K on November 9, 2026, announcing unaudited financial results for the third quarter ended September 30, 2026, furnished via press release as Exhibit 99.1. The filing itself contains only the cover report and signature by CFO Joanna Lv; no specific revenue, profit, or segment figures are disclosed in the filing text, so period-over-period comparisons cannot be calculated from this document.

  • · Filing is a Form 6-K under Rule 13a-16/15d-16 of the Securities Exchange Act of 1934
  • · Commission File Number: 001-38511
  • · Registrant files annual reports under Form 20-F
  • · Principal executive offices located at Level 18, Sohu.com Media Plaza, Block 3, No. 2 Kexueyuan South Road, Haidian District, Beijing 100190, China
  • · Press release dated November 9, 2026 furnished as Exhibit 99.1
  • · Results cover the third quarter ended September 30, 2026 and are unaudited
  • · No financial figures (revenue, income, margins, segment data) are included in the filing text itself
Corebridge Financial, Inc. 8-K neutral materiality 6/10

09-11-2026

Corebridge Financial entered into a Share Repurchase Agreement with Argon Holdco LLC on November 6, 2026, to buy back common stock at $34.09 per share (the November 6 NYSE closing price) for an aggregate purchase price of approximately $110 million, expected to close November 10, 2026 subject to customary conditions. The filing discloses no financial results or period-over-period metrics, so no growth or decline comparisons are available.

  • · Share Repurchase Agreement dated November 6, 2026, between Corebridge Financial, Inc. and Argon Holdco LLC
  • · Repurchase expected to be completed November 10, 2026, subject to customary closing conditions
  • · Share Repurchase Agreement filed as Exhibit 10.1 to the Form 8-K
  • · 8-K signed by Jeannette N. Pina, Deputy General Counsel and Corporate Secretary, dated November 9, 2026
  • · Company incorporated in Delaware; IRS Employer Identification No. 95-4715639; Commission File Number 001-41504
QXO, Inc. 8-K mixed materiality 8/10

09-11-2026

QXO reported preliminary Q3 2026 net sales of approximately $4.90 billion, up 79% from $2.73 billion in Q3 2025, and Adjusted EBITDA of approximately $557 million, up 85% from $301 million, driven largely by the Kodiak (from April 1, 2026) and TopBuild (from July 1, 2026) acquisitions. However, the company still posted a GAAP net loss of approximately $123 million, only modestly improved from a $139 million loss a year earlier, as interest expense jumped to $163 million from $37 million and amortization rose to $288 million from $118 million. Net margin improved to (2.5)% from (5.1)% and Adjusted EBITDA margin edged up to 11.4% from 11.1%, a roughly 0.3-point gain.

  • · Full Q3 2026 results expected to be reported November 12, 2026
  • · Q3 2026 results include Kodiak from April 1, 2026 and TopBuild from July 1, 2026; neither is in Q3 2025 results
  • · Preliminary results are unaudited and subject to completion and may change
  • · QXO describes itself as North America's largest distributor and installer of insulation, second-largest distributor of roofing products, second-largest publicly traded distributor of lumber and building materials, and largest distributor of waterproofing products
  • · Transaction costs rose to $40M from $4M YoY, reflecting M&A activity
  • · Tax line swung to a $27M benefit from a $128M provision a year earlier
  • · Inventory fair value adjustments were -$1M vs $51M in Q3 2025
HDFC BANK LTD 6-K neutral materiality 2/10

09-11-2026

HDFC Bank filed a Form 6-K disclosing the appointment of Mr. V. N. Srivatsan as Chief Compliance Officer of the Bank, per Exhibit 99. The filing is a routine foreign private issuer report signed by Company Secretary Ajay Agarwal on November 06, 2026. No financial results, monetary amounts, or period-over-period metrics were disclosed.

  • · Filing is a Form 6-K under Rule 13a-16/15d-16, Commission File Number 001-15216
  • · Registrant files annual reports under Form 20-F
  • · Principal executive office: HDFC Bank House, Senapati Bapat Marg, Lower Parel, Mumbai 400 013, India
  • · Filing covers the month of November 2026; signature dated November 06, 2026
  • · Appointment disclosed via Exhibit 99
Braveheart Bio, Inc. SC 13G neutral materiality 3/10

09-11-2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. filed a Schedule 13G disclosing beneficial ownership of 7,420,091 shares of Braveheart Bio, Inc. common stock, representing 8.2% of the 90,038,969 shares outstanding as of September 30, 2026. The filing was made under Rule 13d-1(d), indicating a passive investment position with sole voting and dispositive power over all reported shares and no reported change in ownership percentage (0.00% change).

  • · Filing made under Rule 13d-1(d) as a passive investor disclosure
  • · Jiangsu Hengrui holds sole voting and sole dispositive power over all 7,420,091 shares; shared power is zero
  • · Ownership percentage based on 90,038,969 shares outstanding reported in issuer's Form 10-Q filed September 8, 2026
  • · Braveheart Bio is a Delaware-incorporated pharmaceutical preparations company (SIC 2834) headquartered in San Francisco, CA
  • · Jiangsu Hengrui is a non-US filer based in Lianyungang, Jiangsu Province, China
  • · CUSIP: 10567X101; SEC File Number 005-95888
  • · Filing signed by Lau Kin Chun, CFO, dated November 9, 2026
Ucommune International Ltd 6-K neutral materiality 5/10

09-11-2026

Ucommune International Ltd filed a 6-K outlining a proposed increase in authorised share capital structured around a selectable share consolidation (Selected Ratio) ranging from 10:1 down to 2:1. Under each scenario, authorised capital is set at US$2,400,000,000 (10:1), US$1,920,000,000 (8:1), US$1,440,000,000 (6:1), US$960,000,000 (4:1), US$720,000,000 (3:1) or US$480,000,000 (2:1), each divided into 1,000,000,000 shares comprising 999,400,000 Class A, 300,000 Class B and 300,000 Series A Preferred Shares. The filing is a structural/capital-reorganisation disclosure with no operating or financial performance data, so no period-over-period comparison is possible.

  • · Additional Class B and Series A Preferred shares created range from 270,000 each (10:1) down to 150,000 each (2:1)
  • · Par value scales with the Selected Ratio: US$2.40 (10:1), US$1.92 (8:1), US$1.44 (6:1), US$0.96 (4:1), US$0.72 (3:1), US$0.48 (2:1)
  • · Total authorised share count remains fixed at 1,000,000,000 shares across all ratio scenarios
  • · No operating, revenue or earnings figures disclosed in this filing
Flag Ship Acquisition Corp 8-K neutral materiality 3/10

09-11-2026

Flag Ship Acquisition Corp held its Annual General Meeting on November 6, 2026, with 2,853,595 ordinary shares present in person or by proxy, representing approximately 81.10% of shares issued and outstanding and constituting a quorum. Shareholders approved the election of all four director nominees (Matthew Chen, Shan Cui, Pai Liu, Wen He) and ratified Wei, Wei & Co., LLP as independent auditor for fiscal year ending December 31, 2026; the Adjournment Proposal was not presented because sufficient votes existed for the other proposals. Notably, director nominee Shan Cui, Pai Liu and Wen He each received 120,999 withheld votes (about 4.4% of votes cast), while Matthew Chen received only 994 withheld, indicating some shareholder dissent on three of the four nominees.

  • · Record date for the AGM was September 10, 2026; proxy statement dated September 23, 2026
  • · Broker non-votes of 77,392 on the Director Election Proposal
  • · Auditor ratification passed with 2,852,601 for, 994 against, 0 abstentions
  • · Adjournment Proposal was not presented to shareholders as sufficient votes existed for Proposals 1 and 2
  • · Company is an emerging growth company (Rule 405/12b-2)
  • · Company incorporated in Cayman Islands, Commission File Number 001-42138, principal offices at 26 Broadway, Suite 934, New York, NY 10004
  • · Filing signed by Matthew Chen as CEO on November 9, 2026
Zhihu Inc. 6-K neutral materiality 1/10

09-11-2026

Zhihu Inc. filed a routine Form 6-K on November 9, 2026, attaching Exhibit 99.1, its Monthly Return for Equity Issuer and Hong Kong Depositary Receipts under Chapter 19B of the Exchange Listing Rules on Movements in Securities. The filing contains no financial results, guidance, or transaction details and was signed by CFO Han Wang. It is an administrative Hong Kong listing-compliance disclosure with no substantive operational or financial information.

  • · Commission File Number: 001-40253
  • · Principal executive offices at 18 Xueqing Road, Haidian District, Beijing 100083, People's Republic of China
  • · Registrant files annual reports under Form 20-F (not Form 40-F)
  • · Filing covers the month of November 2026
  • · Exhibit 99.1 is the only exhibit attached
FTAI Aviation Ltd. 8-K neutral materiality 7/10

09-11-2026

FTAI Aviation's subsidiary FTAI Aviation Investors LLC issued $1.0 billion of 7.125% Senior Notes due 2034 on November 6, 2026, in a private placement to qualified institutional buyers under Rule 144A/Reg S. Net proceeds will repay in full the Revolving Credit Facility (incurred to fund FTAI's accelerated share repurchase program) without reducing commitments, redeem $500.0 million of the 5.50% 2028 Notes, and pay related fees. The notes are senior unsecured, fully guaranteed by FTAI Aviation and subsidiary guarantors, and carry restrictive covenants; the transaction is a largely leverage-neutral refinancing that extends maturities but adds a 7.125% coupon versus the 5.50% being retired.

  • · Notes mature November 15, 2034; interest payable semi-annually on May 15 and November 15, commencing May 15, 2027
  • · Prior to November 15, 2029, redemption requires a make-whole premium; up to 40% redeemable at 107.125% with equity proceeds
  • · Change of Control Triggering Event gives holders right to require repurchase at 101% of principal plus accrued interest
  • · Notes are senior unsecured, rank pari passu with existing senior unsecured debt, effectively subordinated to secured obligations and structurally subordinated to non-guarantor subsidiaries
  • · Indenture restricts indebtedness, liens, restricted payments, affiliate transactions and asset sales
  • · Revolving Credit Facility is dated April 24, 2026 (Fourth Amended and Restated Credit Agreement)
  • · Notes sold under Rule 144A and Regulation S; not registered under the Securities Act
  • · Issuer is a subsidiary of FTAI Aviation Ltd.; parent guarantee is full and unconditional
Dole plc 8-K mixed materiality 8/10

09-11-2026

Dole plc reported Q3 2026 revenue up 3.8% to $2.4 billion ($2,366.2M) and Adjusted EBITDA up 4.1% to $84.1M, while net income jumped to $48.3M from $13.8M largely on a $48.6M gain from the Ecuador port sale. However, results were mixed: Fresh Fruit revenue fell 8.0% on tariff impacts and adverse weather, EMEA Adjusted EBITDA declined 3.1%, and nine-month Adjusted EBITDA dropped 12.1% to $301.1M versus $322.7M. Management cut full-year 2026 Adjusted EBITDA guidance to $380M-$390M from approximately $400M, citing elevated fuel, shipping and El Niño-related costs.

  • · Nine-month 2026 Adjusted EBITDA fell 6.7% to $301.1M from $322.7M, with Fresh Fruit nine-month Adjusted EBITDA down sharply to $131.6M from $163.2M
  • · Adjusted Net Income for nine months declined to $89.9M from $101.3M, and Adjusted Diluted EPS fell to $0.94 from $1.06
  • · Q3 Adjusted Net Income was $15.0M versus $15.0M prior year (flat), with Adjusted Diluted EPS flat at $0.16
  • · Net Leverage reduced to 1.3x with Net Debt of $491.3M as of September 30, 2026
  • · Free cash flow from continuing operations swung to a $59.3M inflow from a $66.2M outflow in the prior year
  • · Q3 2026 diluted EPS was $0.41 versus $0.05 prior year; nine-month diluted EPS $1.00 versus $0.56
  • · Prior-year Q3 included a $10.2M loss from discontinued operations (Fresh Vegetables) and $10.0M of insurance proceeds
  • · Greenfood Fresh Produce acquisition completed July 2, 2026; preliminary cash consideration less cash acquired was $0.4M
  • · Dividend of $0.085 per share declared November 6, 2026, payable January 6, 2027 to holders of record December 16, 2026
  • · $75.4M remained available under the share repurchase program as of September 30, 2026
  • · Full-year 2026 routine capex guidance reduced to approximately $90M; interest expense guidance maintained at approximately $58M
  • · Higher European shipping fuel costs expected to impact 2026 by approximately $16M versus original expectations
ARGENX SE 6-K neutral materiality 2/10

09-11-2026

argenx SE filed a Form 6-K on November 9, 2026, disclosing that it issued a press release (Exhibit 99.1) on the same date. The filing itself contains no financial figures, operational metrics, or period-over-period comparisons; the substantive content resides in the attached press release, which is not reproduced in the filing text. The report was signed by General Counsel Hemamalini (Malini) Moorthy.

  • · Form 6-K filed under Commission File Number 001-38097 for the month of November 2026
  • · Registrant files annual reports under Form 20-F
  • · Press release attached as Exhibit 99.1, dated November 9, 2026
  • · Information is incorporated by reference into Registration Statements on Forms S-8 (File Nos. 333-225375, 333-258253, 333-274721, and 333-292200)
  • · Principal executive offices located at Laarderhoogtweg 25, 1101 EB Amsterdam, the Netherlands
TOWER SEMICONDUCTOR LTD SC 13G neutral materiality 3/10

09-11-2026

Clal Insurance Enterprises Holdings Ltd filed a Schedule 13G reporting beneficial ownership of 6,331,544 Tower Semiconductor Ordinary Shares, representing 5.6% of the 113,517,666 shares outstanding as of September 30, 2026. However, only 85,519 shares are held for Clal's own account, while 6,246,025 shares are held for the public through provident/pension funds and insurance policies managed by independently-operated subsidiaries, so Clal disclaims beneficial ownership beyond the 85,519 shares. The filing is a passive holding disclosure under Rule 13d-1(c) with no intent to influence control of the issuer.

  • · Filing made under Rule 13d-1(c) (passive investor exemption)
  • · Clal explicitly disclaims beneficial ownership of more than 85,519 shares
  • · Reporting person is an Israeli entity based in Tel Aviv; issuer is based in Migdal Haemek, Israel
  • · Event date of change: November 2, 2026; filing signed November 8, 2026
  • · No acquisition or disposition of control intent certified by reporting person
FG Imperii Acquisition Corp. 425 positive materiality 8/10

09-11-2026

tZERO Group, Inc. and FG Imperii Acquisition Corp. (Nasdaq: FGII) announced a definitive business combination agreement on November 2, 2026, valuing tZERO at $350 million pre-money equity, including up to $25 million contingent on milestones. The combined company could receive up to approximately $231 million held in FG Imperii's trust account before expenses, depending on redemptions, with closing expected in early 2027 and shares expected to trade on NYSE American under 'TZRO'. The newsletter also highlighted tZERO's October CFTC registration of tZERO DCO, LLC as a derivatives clearing organization and a Temple Digital Group selection of tZERO Securities for brokerage and ATS infrastructure, while noting the transaction and proceeds remain subject to shareholder approvals, regulatory consents and closing conditions.

  • · CFTC registered tZERO DCO, LLC as a derivatives clearing organization in October 2026, authorizing clearing of fully collateralized futures, options on futures and swaps
  • · tZERO's separate application to operate a designated contract market (DCM) remains pending
  • · Temple Digital Group selected tZERO Securities as registered broker-dealer and ATS operator for its planned tokenized securities platform on the Canton Network
  • · OCC finalized GENIUS Act stablecoin regulations effective January 18, 2027
  • · SEC proposed allowing registered investment advisors and regulated funds to self-custody crypto assets under certain conditions or use state trust companies as custodians
  • · CFTC announced perpetual futures on individual equities can begin trading on eligible U.S. exchanges as security futures
  • · Combined company shares expected to trade on NYSE American under ticker 'TZRO'
  • · Closing expected in early 2027, subject to shareholder approvals, regulatory consents and other closing conditions
  • · SEC is considering expanding accredited investor eligibility to include CPA, CFA and CFP designations and a potential FINRA-developed examination
BERKSHIRE HATHAWAY INC 10-Q mixed materiality 9/10

09-11-2026

Berkshire Hathaway reported Q3 2026 total revenues of $105,647M, up 11.2% YoY from $94,972M, driven by sales and service revenues (+18.1% to $60,225M) and railroad revenues (+14.3%). However, Q3 net earnings attributable to Berkshire fell 28.2% YoY to $22,112M ($15,502 per Class A share) from $30,796M, as investment gains dropped to $11,946M from $21,939M and insurance underwriting costs rose. First nine months net earnings rose 21.2% to $57,885M, helped by equity method earnings swinging to +$1,403M from -$4,289M.

  • · Insurance and Other cash and cash equivalents fell to $36,034M from $47,719M at year-end 2025
  • · Payable for purchases of U.S. Treasury Bills jumped to $20,489M from $167M
  • · Insurance losses and LAE rose to $14,839M in Q3 2026 from $13,735M
  • · Selling, general and administrative expenses rose to $7,888M in Q3 2026 from $6,285M
  • · Equity method earnings swung to +$1,403M in 9M 2026 from -$4,289M in 9M 2025
  • · Berkshire repurchased $9,647M of stock in Q3 2026 and $13,757M in 9M 2026
  • · Total shareholders' equity rose to $763,628M from $719,703M at year-end 2025
  • · Cash and cash equivalents and restricted cash fell to $41,658M from $77,111M a year earlier
  • · Acquisitions of businesses totaled $16,205M in 9M 2026 vs $918M in 9M 2025
  • · Average equivalent Class A shares outstanding declined to 1,426,372 from 1,438,223
Tivic Health Systems, Inc. 8-K neutral materiality 4/10

09-11-2026

Valion Bio, Inc. (formerly Tivic Health Systems, now trading as VBIO on Nasdaq) closed a $700,000 tranche of its Series B Preferred financing with 3i, LP on November 6, 2026, issuing 700 Series B Preferred Shares and warrants to buy 21,539 common shares at $0.5182. The Fifth 3i Side Letter extends the outside closing date under the up-to-$8,400,000 Series B program to December 9, 2027, leaving up to 1,550 Series B shares ($1,550,000) still available to 3i. The raise is small relative to the company's broader capital structure, which includes $13,637,000 already drawn on a $75,000,000 Series C program and a $16,253,147.10 senior secured convertible note, and the closing triggers anti-dilution price adjustments across existing Series B, Series C and note securities.

  • · Warrant exercise price for the closing tranche is $0.5182 per share.
  • · Company agreed to file a resale registration statement within 30 days of closing and have it effective within 60 days.
  • · Closing triggers price adjustments to conversion/exercise prices of Series B, Series C, the Note and Note Warrant, potentially issuing additional securities.
  • · Closing conditioned on continued Nasdaq Capital Market listing and compliance.
  • · Company changed its name from Tivic Health Systems, Inc. to Valion Bio, Inc.; ticker is now VBIO.
  • · Filing signed by Interim CEO Dean Zikria; side letter executed by COO Lisa Wolf.
  • · Governing law is New York; agreement executed November 6, 2026 and filed November 9, 2026.
Option Care Health, Inc. DEFM14A neutral materiality 8/10

09-11-2026

Option Care Health filed a preliminary DEFM14A proxy statement for a Special Meeting where stockholders will vote on adopting a Merger Agreement under which Merger Sub will merge into the Company, leaving it a wholly owned subsidiary of Parent. The Merger is expected to close in the first half of calendar year 2027, subject to regulatory approvals and the stockholder vote; upon completion, OPCH shares will be delisted from Nasdaq and deregistered under the Exchange Act. The filing details appraisal rights under DGCL Section 262, termination fee obligations on both sides, and risks including potential regulatory delays, litigation, and management disruption; no financial consideration or purchase price is disclosed in this excerpt.

  • · Merger expected to close in first half of calendar year 2027, subject to regulatory approvals and stockholder approval
  • · Upon closing, OPCH shares will be delisted from Nasdaq and registration under the Exchange Act terminated
  • · Company may owe Parent a Company Termination Fee to pursue an alternative transaction; Parent may owe the Company a Parent Termination Fee under certain circumstances
  • · Stockholders who do not vote in favor and properly demand appraisal may seek 'fair value' plus interest in Delaware Court of Chancery
  • · If the Merger is not completed, the Company remains an independent public company and stockholders receive no payment
  • · Proxy solicitor is Innisfree M&A Incorporated, 500 Fifth Avenue, 21st Floor, New York, NY 10110
  • · Company operates in one segment (infusion services) with principal offices in Bannockburn, IL
  • · Risk factors reference the Form 10-K for fiscal year ended December 31, 2025, filed February 24, 2026
Laredo Oil, Inc. 8-K neutral materiality 5/10

09-11-2026

Laredo Oil stockholders holding a majority (51.4%) of outstanding shares approved by written consent on October 29, 2026 an amendment to the Certificate of Incorporation increasing authorized common stock from 120,000,000 to 350,000,000 shares, a nearly 3x increase. The Board had approved the Amendment on October 28, 2026, and the Certificate of Amendment was filed with Delaware on November 4, 2026. Notably, 48.6% of outstanding shares (41,781,139 shares) did not participate in the consent, and no shares were voted against or abstained.

  • · Authorized common stock increased from 120,000,000 to 350,000,000 shares (approximately 2.9x increase)
  • · Board of Directors approved the Amendment on October 28, 2026
  • · Certificate of Amendment filed with Delaware Secretary of State on November 4, 2026
  • · Written consent executed in lieu of a special meeting under Section 228 of Delaware General Corporation Law
  • · Company will provide prompt notice to stockholders who did not execute the written consent per Section 228(e)
  • · No shares were voted against the Amendment and none abstained
  • · Company has no securities registered under Section 12(b); common stock trades under symbol LRDC on no registered exchange
Research Alliance Corp V S-1 neutral materiality 6/10

09-11-2026

Research Alliance Corp V filed an S-1 registration statement on November 6, 2026 for an initial public offering of 6,200,000 public shares, with trust account funds initially anticipated at $10.00 per public share. The SPAC structure includes founder shares, private placement shares, and a 24-month deadline to complete an initial business combination, with redemption rights capped at 15% of public shares for holders acting in concert absent company consent. Approval of a business combination requires an ordinary resolution majority, with the sponsor and management agreeing to vote their shares in favor; assuming all shares are voted, 2,421,942 public shares (39.1% of the 6,200,000 sold) would need to vote in favor.

  • · The sponsor and management team have agreed to waive redemption rights with respect to their founder shares, private placement shares and public shares in connection with the business combination and certain charter amendments.
  • · Redemptions may be conducted via a shareholder vote under Regulation 14A or via tender offer under Rule 13e-4 and Regulation 14E.
  • · If public shareholders tender more shares than offered to purchase, the tender offer will be withdrawn and the business combination will not be completed.
  • · The per-share redemption amount will not be reduced by deferred underwriting commissions payable to the underwriter.
  • · No redemption rights apply to private placement shares upon completion of the initial business combination.
  • · The company will not proceed with redeeming public shares if a business combination does not close.
  • · Initial shareholders, directors, officers, advisors or affiliates may purchase securities outside the redemption offer to increase the likelihood of shareholder approval or satisfy a minimum net worth/cash closing condition, which could reduce the public float.
Datavault AI Inc. 8-K mixed materiality 7/10

09-11-2026

Datavault AI overhauled its leadership effective immediately: Brett Moyer was appointed CEO and President, succeeding Nathaniel Bradley, who was removed as CEO and President on November 1, 2026 but remains a board member. Kimberly Briskey was named Chair of the Board, Sri Peruvemba Vice Chair, Teri Gallo COO, Stanley Mbugua CFO (succeeding Moyer), and Christopher R. Hardt Chair of the Audit Committee; former executive Sonia Choi is no longer with the company. The filing disclosed no financial figures, but the release flags risks including a restatement of previously issued financial statements, Nasdaq minimum bid price compliance and potential reverse stock split, and possible litigation tied to the executive removals; Q3 2026 results will be reported on a date to be announced.

  • · Nathaniel Bradley was removed as CEO and President on November 1, 2026, and remains a member of the Board
  • · Sonia Choi, formerly an executive, is no longer with the Company and is not authorized to act on its behalf
  • · Brett Moyer served as CFO from January 2025 until his CEO appointment and was Chairman of the Board until November 6, 2026
  • · Moyer was a founding member of WiSA Technologies and served as its President and CEO from August 2010 through December 2024
  • · Teri Gallo has served as CEO of NYIAX since 2024, leading two acquisitions and its merger with Datavault
  • · Stanley Mbugua was previously Chief Accounting Officer at Presto Automation (March 2023–August 2024), Skillz (September 2021–March 2023) and Rimini Street (September 2017–June 2021)
  • · Christopher R. Hardt is a CPA and former PwC partner who led Consumer Markets SEC Services in PwC's National Office
  • · Forward-looking risk disclosures cite restatement of previously issued financial statements, Nasdaq minimum bid price compliance, timing/effect of any reverse stock split, and potential litigation over officer removals
  • · Q3 2026 results timing and any conference call/webcast details will be announced separately
TruGolf Holdings, Inc. 8-K/A neutral materiality 5/10

09-11-2026

TruGolf Holdings filed Amendment No. 2 to its 8-K to supplement Item 9.01 with financial statements for its October 8, 2026 acquisition of Polymath Research Inc. (Canada), originally agreed August 17, 2026. The filing includes Polymath's audited FY2025 and FY2024 consolidated financial statements, unaudited interim statements for the three and six months ended June 30, 2026 and 2025, and unaudited pro forma combined financials for TruGolf plus Polymath. The amendment contains no new narrative disclosure or financial figures in the body text beyond exhibit descriptions, so no period-over-period performance can be assessed from this filing alone.

  • · Acquisition of Polymath Research Inc. consummated October 8, 2026; acquisition agreement dated August 17, 2026, as amended
  • · Original 8-K filed October 9, 2026; Amendment No. 1 filed October 28, 2026; this Amendment No. 2 filed November 6, 2026
  • · Exhibit 99.1: Audited consolidated financial statements of Polymath for years ended December 31, 2025 and 2024
  • · Exhibit 99.2: Unaudited condensed consolidated financial statements of Polymath for three and six months ended June 30, 2026 and 2025
  • · Exhibit 99.3: Unaudited pro forma condensed combined financials of TruGolf as of and for year ended December 31, 2025 and six months ended June 30, 2026
  • · Exhibit 23.1: Consent of BCRG Group, Certified Public Accountants & Consultants, dated November 6, 2026
  • · TruGolf is an emerging growth company and a Nevada corporation (Commission File No. 001-40970; IRS EIN 85-3269086)
  • · Headquarters: 60 North 1400, West Centerville, Utah 84014; phone (801) 298-1997
Sonic Holdco, Inc. S-4/A mixed materiality 8/10

09-11-2026

Sonic Holdco, Inc. ("Parent") filed an S-4/A for a two-step, interdependent merger in which Synlogic and Caldera will combine under a newly formed holding company, with Caldera treated as the accounting acquirer in a reverse recapitalization and Parent shares expected to list on NYSE American under the symbol "CALD." The deal faces significant execution risk: Synlogic is a non-operating shell delisted from Nasdaq with a material weakness in internal controls as of December 31, 2025, while Caldera is an early clinical-stage biopharma with no product revenue, recurring net losses, and dependence on its sole clinical candidate CLD-423. Completion is conditioned on NYSE American listing approval, the Concurrent Financing, and other conditions outside the parties' control, and failure could push Synlogic toward dissolution and liquidation.

  • · Synlogic's securities have been delisted from Nasdaq, limiting investors' ability to transact
  • · Synlogic has identified a material weakness in internal control over financial reporting as of December 31, 2025
  • · Synlogic has discontinued all product development activities and is a non-operating shell company
  • · Caldera has not generated any product revenue and has incurred net losses in every period since inception
  • · Caldera is substantially dependent on CLD-423, a bispecific antibody with a novel monovalent format and limited clinical/regulatory precedent
  • · Parent is an emerging growth company electing the extended transition period for new accounting standards, making its financials potentially non-comparable
  • · Parent Common Stock is not currently traded or quoted on any exchange; listing on NYSE American is a closing condition that may be waived by agreement among the parties without re-solicitation
  • · If the Mergers fail and no superior alternative exists, the Synlogic Board may pursue dissolution and liquidation
  • · Stockholders of Synlogic and Caldera have appraisal rights under Section 262 of the DGCL
  • · If the Mergers do not qualify as an exchange under Section 351(a) of the Code, stockholders may recognize substantial taxable gain
Third Point Private Capital Income Fund 8-K neutral materiality 4/10

09-11-2026

Third Point Private Capital Income Fund sold 160,000 Class S common shares to Delticus Opportunities Fund LLC, an affiliate of its investment adviser, at $25.00 per share for $4,000,000 in an unregistered offering finalized November 3, 2026. The sale was part of a $15,000,000 common subscription commitment and was paired with a separate $225,000,000 preferred share (seed share) subscription commitment from the same affiliate. No underwriting discounts or commissions were paid, and the shares were issued under Section 4(a)(2)/Regulation D accredited-investor exemptions.

  • · The 160,000 Class S shares represent approximately 2.7% of the $15,000,000 common subscription commitment, leaving roughly $11,000,000 undrawn.
  • · The preferred share commitment ($225,000,000) is 15x larger than the common share commitment ($15,000,000).
  • · Delticus is an affiliate of the Fund's investment adviser, Third Point Private Capital LLC, making this a related-party transaction.
  • · The sale date was October 23, 2026, with the final share count determined November 3, 2026.
  • · The Fund is an emerging growth company incorporated in Delaware with Commission File Number 814-01979.
  • · No securities are registered under Section 12(b) of the Act.
Hansen & Associates Financial Group, Inc. 13F-HR neutral materiality 3/10

09-11-2026

Hansen & Associates Financial Group, Inc. filed its quarterly 13F-HR for the period ended September 30, 2026, disclosing 48 holdings with a total reported value of $175,351,904. The portfolio is heavily concentrated in mega-cap technology (NVIDIA $3.05M, Microsoft $2.96M, Apple $2.55M, Amazon $2.55M) and broad/sector ETFs, while the largest single position is a $55.58M allocation to the First Trust Enhanced New ETF and a $24.61M iShares Europe ETF stake. Notably, the book is defensively tilted with large low-volatility, quality-factor, and VIX mid-term futures positions ($11.36M), while core single-stock bets like Micron ($274,503), Target ($297,733), and Palantir ($447,851) remain comparatively small.

  • · All 48 positions are held solely (SOLE voting authority) with zero shared or discretionary-other voting authority
  • · Portfolio shows a barbell structure: ~$80M+ in broad/sector ETFs versus ~$25M in individual mega-cap tech stocks
  • · Defensive/volatility hedges include ProShares VIX Mid-Term Futures ($11.36M) and Invesco S&P 500 Low Volatility ETF ($2.54M)
  • · Smallest positions include Snowflake ($210,504), Super Micro ($210,813), and SpaceX ($236,199)
  • · Filer is a California-based registered investment adviser (CRD 801-122580) based in Roseville, CA
  • · Filing signed by Mark Hansen, CCO, dated 11-06-2026
Yunqi Capital Ltd 13F-HR neutral materiality 3/10

09-11-2026

Yunqi Capital Ltd filed its Q3 2026 13F-HR disclosing three equity positions as of September 30, 2026: STAAR Surgical (3,257,130 shares), Power Solutions International (521,904 shares), and Lufax Holding sponsored ADRs (10,950,138 shares). The filing is a routine quarterly holdings report with no period-over-period comparison data provided, so no growth or decline metrics can be calculated.

  • · All three positions are held with sole voting and sole dispositive authority (no shared or none authority reported)
  • · Filing period of report is September 30, 2026; filed November 9, 2026
  • · Filer is a Hong Kong-based entity (Unit 3703, 37/F, AIA Tower, 183 Electric Road, North Point)
  • · SEC file number 028-22309; accession 0001912273-26-000005
  • · No market values (USD) were included in the provided filing text, so position values cannot be quantified
SPACCircle Acquisition Corp. 8-K neutral materiality 3/10

09-11-2026

SPACCircle Acquisition Corp. announced that, effective November 10, 2026, holders of its IPO units may elect to separately trade the Class A ordinary shares, redeemable warrants, and rights bundled in each unit. The Class A shares, warrants, and rights are expected to trade on Nasdaq under the symbols SCQC, SCQCW, and SCQCR respectively, while unseparated units continue trading as SCQCU. The filing is a routine administrative update with no financial results or deal terms disclosed; the preliminary 'Merger/Acquisition' classification is not supported as no business combination was announced.

  • · Separate trading commences November 10, 2026
  • · Units not separated will continue to trade under symbol SCQCU on the Nasdaq Global Market
  • · Holders must have their brokers contact transfer agent VStock Transfer, LLC to separate Units
  • · Each Unit consists of one Class A ordinary share, one redeemable warrant, and one right
  • · Each right entitles holder to receive one-half (1/2) of one Class A ordinary share upon consummation of the initial business combination
  • · Press release dated November 6, 2026 filed as Exhibit 99.1
  • · Company is an emerging growth company (checked)
ZA Acquisition Corp. I S-1 neutral materiality 3/10

09-11-2026

ZA Acquisition Corp. I (formerly Z2 Acquisition Corp. I, renamed April 7, 2026) filed an S-1 registration statement on November 9, 2026 for an initial public offering of units. The Delaware blank-check company, based in Red Bank, NJ, is a SPAC with no operations and will hold proceeds in trust pending a business combination. The filing is a standard IPO registration with no operating financials or period-over-period performance data disclosed in the provided content.

  • · Company was formerly named Z2 Acquisition Corp. I; name changed April 7, 2026
  • · Incorporated in Delaware with EIN 414936094
  • · SEC File Number 333-299911; Film Number 261533405
  • · Classified under SIC 6770 (Blank Checks)
  • · Business address: 10 Drs James Parker Blvd, Suite 202, Red Bank, NJ 07701
  • · Registration statement contains 73 documents
  • · Filing covers redemption scenarios ranging from no redemption to 100% of maximum redemption
  • · Sponsor entity referenced as ZA Sponsor I LLC
InterPrivate Investment Partners V, Inc. 10-Q mixed materiality 4/10

09-11-2026

InterPrivate Investment Partners V, Inc., a blank-check shell company, reported Q3 2026 net income of $1,671,223 and nine-month net income of $1,954,881, driven entirely by $1,881,960 (Q3) and $2,331,994 (nine-month) of interest earned on the $203,581,994 held in its Trust Account. However, operating losses widened with general and administrative expenses of $210,737 for Q3 and $377,113 for the nine months, and the company posted a shareholders' deficit of $7,646,665 as of September 30, 2026 versus positive equity of $7,093 at year-end 2025, reflecting $16,172,386 of accretion to redemption value. The company completed its IPO during the period, raising $197,750,000 net of underwriting discounts plus $5,400,000 from private placement units, while carrying an $8,575,000 deferred underwriting fee.

  • · Company is classified as a shell company and emerging growth company; non-accelerated filer.
  • · Warrants are exercisable for Class A ordinary shares at $11.50 per share.
  • · Class A shares subject to possible redemption valued at $10.12 per share as of September 30, 2026.
  • · Net cash used in operating activities was $409,383 for the nine months ended September 30, 2026.
  • · Deferred offering costs paid through related-party promissory note totaled $135,706.
  • · Repayment of promissory note to related party was $199,751 during the period.
  • · Accumulated deficit grew to $7,647,222 from $17,907 at December 31, 2025.
  • · No preference shares issued or outstanding; 1,000,000 authorized.
DRIVE WEALTH MANAGEMENT, LLC 13F-HR neutral materiality 3/10

09-11-2026

Drive Wealth Management, LLC filed its Q3 2026 13F-HR (period ended September 30, 2026) on November 9, 2026, disclosing a highly diversified portfolio spanning mega-cap equities, ETFs, and fixed-income funds. The filing is a combination report covering 508 total holdings, with positions reported across two other managers (Townsquare Capital LLC and AQR Capital Management LLC). Largest disclosed positions include Apple (~48,964 shares plus additional share classes), Amazon (~33,553 shares), Broadcom (~15,449 shares), and Alphabet Class A (~20,265 shares), alongside substantial ETF allocations to iShares, Dimensional, and JPMorgan products.

  • · Filing is a 13F combination report incorporating holdings of Townsquare Capital LLC (CIK 0001761755) and AQR Capital Management LLC (CIK 0001167557)
  • · Filer CIK: 0001952781; SEC File Number 028-22701; Film Number 261533376
  • · Filer address: 3333 N Digital Drive #700, Lehi, UT 84043; phone 801-901-6150
  • · Portfolio shows heavy ETF usage including iShares Treasury bond ladder ETFs (Dec 2026 through Dec 2031 maturities)
  • · Notable alternative/speculative positions include Fidelity Wise Origin Bitcoin Fund (11,676 shares), CoinShares PLC (11,728 shares), and IREN Limited (8,110 shares)
  • · Significant international exposure via ADRs: HSBC (8,315), ICICI Bank (12,251), Banco Santander Brasil (15,085), Deutsche Bank (14,523), ING Groep (12,658)
  • · Multiple share classes held for same issuers (e.g., Alphabet Class A and C, Amazon, Apple, Broadcom, Berkshire Class B) indicating multi-manager aggregation
CALIFORNIA FIRST LEASING CORP 13F-HR neutral materiality 3/10

09-11-2026

California First Leasing Corp filed its Q3 2026 (period ended 09-30-2026) 13F-HR institutional holdings report disclosing 40 positions with an aggregate reported value of $460,578,052. The portfolio is heavily concentrated in mega-cap technology and financials, led by Marvell Technology (13,080,000 shares), SLB (12,900,000 shares), Bank of America (11,750,000 shares), Uber (11,310,300 shares) and Wells Fargo (10,640,000 shares). The filing is a routine quarterly holdings disclosure with no period-over-period comparison data provided, so no change metrics can be calculated.

  • · Largest disclosed positions by share count: Marvell Technology 13,080,000 shares; SLB 12,900,000 shares; Bank of America 11,750,000 shares; Uber 11,310,300 shares; Wells Fargo 10,640,000 shares
  • · Other large holdings include Exxon Mobil 16,080,000 shares, Zeta Global 25,316,300 shares, and On Holding AG 8,410,000 shares
  • · Portfolio spans technology, financials, healthcare, energy, consumer and industrials sectors
  • · Filing signed by S. Leslie Jewett, CFO, dated 11-06-2026; SEC file number 028-21848
  • · No quarter-over-quarter position changes or share-count deltas are disclosed in this filing
Hyperscale Data, Inc. 8-K neutral materiality 6/10

09-11-2026

Hyperscale Data, Inc. entered a Note Purchase Agreement dated November 6, 2026 with Esousa Group Holdings, LLC for the issuance and sale of convertible notes, with conversion into Class A common stock ($0.001 par) under an effective Form S-3 registration statement (File No. 333-291595). The filing discloses capitalization of 236,001,576 common shares outstanding against 474,940,643 shares reserved for convertible securities, plus 24,553,809 Class B shares and multiple preferred series outstanding. No principal amount, interest rate, or conversion price for the notes is specified in the excerpt, and the company made standard representations that it is not Insolvent and has no undisclosed material events.

  • · Note Purchase Agreement effective date is November 6, 2026; 8-K filed November 9, 2026
  • · Notes are convertible into Class A common stock and were issued in reliance on an effective Form S-3 registration statement
  • · No principal amount, interest rate, maturity, or conversion price for the notes is disclosed in the provided excerpt
  • · 474,940,643 common shares reserved for convertible securities represent roughly 2x the 236,001,576 shares currently outstanding, indicating significant potential dilution
  • · No shares of common stock are held in treasury
  • · Company represented it is not Insolvent on a consolidated basis and has no undisclosed material events or liabilities
  • · Company confirmed no delisting or suspension communications from the SEC or Principal Market in the prior two years
  • · No dividends declared or paid since the most recent audited 10-K; no material asset sales or capex outside ordinary course

Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 50 filings

$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: US SEC Filings Daily Market Digest

🇺🇸 More from United States

View all →